Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBT (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBT for 4 consecutive years, with -$34.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 10.21% to -$34.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$24.7 million, a 81.11% increase, with the full-year FY2024 number at -$124.8 million, up 7.43% from a year prior.
  • EBT was -$34.4 million for Q3 2025 at Century Therapeutics, down from -$32.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $76.6 million in Q1 2025 to a low of -$40.3 million in Q4 2023.
  • A 4-year average of -$25.4 million and a median of -$31.6 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: fell 27.23% in 2023, then surged 372.83% in 2025.
  • Century Therapeutics' EBT stood at -$31.6 million in 2022, then dropped by 27.23% to -$40.3 million in 2023, then rose by 14.83% to -$34.3 million in 2024, then fell by 0.37% to -$34.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EBT are -$34.4 million (Q3 2025), -$32.5 million (Q2 2025), and $76.6 million (Q1 2025).